News
06-07-2010, 12:30 AM
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
More... (http://www.news-medical.net/news/20100607/bioTheranostics-presents-positive-outcomes-from-CancerTYPE-ID-Breast-Cancer-Index-clinical-studies.aspx)
More... (http://www.news-medical.net/news/20100607/bioTheranostics-presents-positive-outcomes-from-CancerTYPE-ID-Breast-Cancer-Index-clinical-studies.aspx)